Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
NOVT 
Novanta Inc (NOVT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/14/2025: NOVT (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $141.5
1 Year Target Price $141.5
| 1 | Strong Buy |
| 2 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -26.13% | Avg. Invested days 52 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/14/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 3.71B USD | Price to earnings Ratio 61.02 | 1Y Target Price 141.5 |
Price to earnings Ratio 61.02 | 1Y Target Price 141.5 | ||
Volume (30-day avg) 4 | Beta 1.5 | 52 Weeks Range 98.76 - 184.11 | Updated Date 10/14/2025 |
52 Weeks Range 98.76 - 184.11 | Updated Date 10/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 1.69 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 6.41% | Operating Margin (TTM) 11.4% |
Management Effectiveness
Return on Assets (TTM) 5.49% | Return on Equity (TTM) 8.16% |
Valuation
Trailing PE 61.02 | Forward PE - | Enterprise Value 4117772400 | Price to Sales(TTM) 3.88 |
Enterprise Value 4117772400 | Price to Sales(TTM) 3.88 | ||
Enterprise Value to Revenue 4.3 | Enterprise Value to EBITDA 22.47 | Shares Outstanding 35973631 | Shares Floating 35635479 |
Shares Outstanding 35973631 | Shares Floating 35635479 | ||
Percent Insiders 0.98 | Percent Institutions 106.43 |
Upturn AI SWOT
Novanta Inc
Company Overview
History and Background
Novanta Inc. was founded in 1967 as General Scanning. It has evolved through acquisitions and strategic shifts to become a leading provider of precision photonic and motion control components and subsystems for industrial and medical applications.
Core Business Areas
- Photonics: Provides precision laser beam steering, scanning, and related solutions.
- Vision: Offers embedded vision solutions, including optical coherence tomography (OCT) and 3D scanning technologies.
- Precision Motion: Delivers precision motion control systems for medical and advanced industrial applications.
Leadership and Structure
The company is led by Matthijs Glastra (CEO). The organizational structure includes business units focused on specific product lines and markets, supported by central functions like finance, sales, and engineering.
Top Products and Market Share
Key Offerings
- Laser Beam Steering Components: Includes galvanometers and scan heads for laser marking, cutting, and welding applications. Competitors include Cambridge Technology, Scanlab. Market share data varies depending on the specific sub-segment, but Novanta is generally considered a major player.
- Optical Coherence Tomography (OCT) Systems: Used in medical imaging for ophthalmology and dermatology. Competitors include Thorlabs, Topcon. Market share data varies, but Novanta is considered a leading provider in specialized areas.
- Miniature Motion Control Stages: Precision motion stages for advanced manufacturing and medical applications. Competitors include Aerotech, PI (Physik Instrumente). Market share data not readily available as it's a niche market.
Market Dynamics
Industry Overview
The precision photonics and motion control industry is driven by increasing automation, advancements in medical technology, and growing demand for high-precision manufacturing processes. Key trends include miniaturization, integration, and connectivity.
Positioning
Novanta is positioned as a technology leader providing high-precision components and subsystems to original equipment manufacturers (OEMs) in industrial and medical markets. Their competitive advantage lies in their deep application knowledge and engineering expertise.
Total Addressable Market (TAM)
The estimated TAM for Novanta's core markets is in the billions of dollars. The company is well-positioned to capture a significant portion of this TAM through continued innovation and strategic acquisitions.
Upturn SWOT Analysis
Strengths
- Strong market position in niche segments
- Diverse product portfolio
- Established relationships with OEMs
- Technical expertise and innovation
- Strategic acquisition strategy
Weaknesses
- Exposure to cyclical industries
- Reliance on key suppliers
- Potential integration risks from acquisitions
- Customer concentration
Opportunities
- Expanding into new geographic markets
- Developing new products and applications
- Acquiring complementary businesses
- Benefiting from increasing automation trends
Threats
- Economic downturns
- Intense competition
- Technological obsolescence
- Fluctuations in currency exchange rates
Competitors and Market Share
Key Competitors
- IPG
- COHR
- MKS
Competitive Landscape
Novanta competes with a mix of large and small companies, differentiated by their focus on specific applications and technologies. Novanta's strength lies in its ability to provide integrated solutions and its established relationships with OEMs.
Major Acquisitions
Celera Motion
- Year: 2018
- Acquisition Price (USD millions): 147.5
- Strategic Rationale: Expanded Novanta's precision motion control capabilities.
Growth Trajectory and Initiatives
Historical Growth: Novanta has experienced growth through a combination of organic initiatives and strategic acquisitions.
Future Projections: Future growth projections would be based on analyst estimates which are constantly updated.
Recent Initiatives: Recent initiatives include acquisitions, product development, and expansion into new markets.
Summary
Novanta is a company with a diversified product portfolio targeting industrial and medical end markets. Their growth strategy focuses on both organic innovation and strategic acquisitions. Key strengths include their technology expertise and customer relationships; however, they face risks related to economic cycles and competition. Novanta needs to manage acquisition integration carefully and mitigate its reliance on key customers.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Novanta Inc. Investor Relations
- SEC Filings
- Analyst Reports
- Industry Research Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market share data and financial figures are estimates based on publicly available information and may not be precise. Consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Novanta Inc
Exchange NASDAQ | Headquaters Bedford, MA, United States | ||
IPO Launch date 2016-01-04 | CEO & Chairman of the Board Mr. Matthijs Glastra | ||
Sector Technology | Industry Scientific & Technical Instruments | Full time employees 3000 | Website https://www.novanta.com |
Full time employees 3000 | Website https://www.novanta.com | ||
Novanta Inc., together with its subsidiaries, provides precision medicine, precision manufacturing, medical solutions, robotics and automation solutions, and advanced surgery solutions in the United States and internationally. It operates in two segments, Automation Enabling Technologies and Medical Solutions. The Precision Medicine and Manufacturing segment designs, manufactures, and markets laser beam delivery components, laser beam delivery solutions, CO2 lasers, solid state lasers, ultrafast lasers, optical and inductive encoders, precision motors, integrated stepper motors, servo drives, motion control solutions, intelligent robotic end-of-arm technology solutions, and air bearing spindles. This segment serves advanced industrial processes, advanced industrial and medical robotics, other medical and life science automation applications, and medical laser procedures, such as ophthalmology applications. The Medical Solutions segment provides a range of medical grade technologies, including medical insufflators, pumps, and related disposables; laser beam delivery solutions; video processing, streaming, and capture; machine vision technologies; radio frequency identification (RFID) technologies; barcode identification technologies; thermal chart recorders; light and color measurement technologies; touch panel displays; and advanced motion control solutions. The company sells its products through its direct sales force and distributors under the Cambridge Technology, Synrad, Laser Quantum, ARGES, WOM, NDS, Med X Change, Reach Technology, JADAK, ThingMagic, Photo Research, General Scanning, ATI Industrial Automation, Celera Motion, IMS, MicroE, Applimotion, Zettlex, Ingenia, and Westwind brands. The company was formerly known as GSI Group, Inc. and changed its name to Novanta Inc. in May 2016. Novanta Inc. was incorporated in 1968 and is headquartered in Bedford, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.